Exposure‐response Analysis for Spontaneously Reported Dizziness in Pregabalin‐treated Patient With Generalized Anxiety Disorder

To describe the pregabalin exposure–adverse event (AE) (dizziness) relationship in patients with generalized anxiety disorder, separate models were developed for the incidence of AE and for the conditional severity of AE, given that an AE has occurred using patient data from six clinical studies. The incidence component was modeled using a nonlinear logistic regression model. The conditional severity component was modeled as an ordered categorical variable with a proportional odds model to capture the severity on any given day. A Markov element was introduced to account for the correlation between neighboring observations. The proportional odds model including a time course of appearance and disappearance of AE could adequately describe the time course of probability of dizziness. Incorporating a transition model including Markov elements improved the model fit and greatly improved the predictability of the time course of probability of dizziness.

[1]  T. Pugsley,et al.  Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. , 2000, The Journal of pharmacology and experimental therapeutics.

[2]  J. Offord,et al.  The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the Subunit of a Calcium Channel (*) , 1996, The Journal of Biological Chemistry.

[3]  L B Sheiner,et al.  Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.

[4]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) , 1999, Epilepsy Research.

[5]  H. Clusmann,et al.  Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex , 2002, Neuropharmacology.

[6]  A. McKnight,et al.  Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices , 2001, Pain.

[7]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.

[8]  S. Borosky,et al.  Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin , 2000, Neuroscience Letters.

[9]  Lynn McFadyen,et al.  A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  D. Welty,et al.  Pharmacokinetics and pharmacodynamics of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock , 1977 .